112 related articles for article (PubMed ID: 38070127)
21. Huaier aqueous extract inhibits cervical cancer cell proliferation via JNK/p38 pathway.
Yan L; Liu X; Yin A; Wei Y; Yang Q; Kong B
Int J Oncol; 2015 Sep; 47(3):1054-60. PubMed ID: 26201539
[TBL] [Abstract][Full Text] [Related]
22. Myosin 1b promotes cell proliferation, migration, and invasion in cervical cancer.
Zhang HR; Lai SY; Huang LJ; Zhang ZF; Liu J; Zheng SR; Ding K; Bai X; Zhou JY
Gynecol Oncol; 2018 Apr; 149(1):188-197. PubMed ID: 29395313
[TBL] [Abstract][Full Text] [Related]
23. Molecular iodine inhibits the expression of stemness markers on cancer stem-like cells of established cell lines derived from cervical cancer.
Bigoni-Ordóñez GD; Ortiz-Sánchez E; Rosendo-Chalma P; Valencia-González HA; Aceves C; García-Carrancá A
BMC Cancer; 2018 Sep; 18(1):928. PubMed ID: 30257666
[TBL] [Abstract][Full Text] [Related]
24. CYT-Rx20 Inhibits Cervical Cancer Cell Growth and Migration Through Oxidative Stress-Induced DNA Damage, Cell Apoptosis, and Epithelial-to-Mesenchymal Transition Inhibition.
Wang YY; Hsieh PW; Chen YK; Hu SC; Hsu YL; Tsai CH; Yuan SF
Int J Gynecol Cancer; 2017 Sep; 27(7):1306-1317. PubMed ID: 30814237
[TBL] [Abstract][Full Text] [Related]
25. Effect of ex vivo-expanded γδ-T cells combined with galectin-1 antibody on the growth of human cervical cancer xenografts in SCID mice.
Li H; Wang Y; Zhou F
Clin Invest Med; 2010 Oct; 33(5):E280-9. PubMed ID: 20926034
[TBL] [Abstract][Full Text] [Related]
26. Phloretin suppresses metastasis by targeting protease and inhibits cancer stemness and angiogenesis in human cervical cancer cells.
Hsiao YH; Hsieh MJ; Yang SF; Chen SP; Tsai WC; Chen PN
Phytomedicine; 2019 Sep; 62():152964. PubMed ID: 31153059
[TBL] [Abstract][Full Text] [Related]
27. Knockdown of MIR9‑3HG inhibits proliferation and promotes apoptosis of cervical cancer cells by miR‑498 via EP300.
Li F; Liang Y; Ying P
Mol Med Rep; 2021 Nov; 24(5):. PubMed ID: 34468010
[TBL] [Abstract][Full Text] [Related]
28. Curcumin decreases epithelial‑mesenchymal transition by a Pirin‑dependent mechanism in cervical cancer cells.
Aedo-Aguilera V; Carrillo-Beltrán D; Calaf GM; Muñoz JP; Guerrero N; Osorio JC; Tapia JC; León O; Contreras HR; Aguayo F
Oncol Rep; 2019 Nov; 42(5):2139-2148. PubMed ID: 31436299
[TBL] [Abstract][Full Text] [Related]
29. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
30. The Role of Biomarkers for the Prediction of Response to Checkpoint Immunotherapy and the Rationale for the Use of Checkpoint Immunotherapy in Cervical Cancer.
Otter SJ; Chatterjee J; Stewart AJ; Michael A
Clin Oncol (R Coll Radiol); 2019 Dec; 31(12):834-843. PubMed ID: 31331818
[TBL] [Abstract][Full Text] [Related]
31. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
32. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
[TBL] [Abstract][Full Text] [Related]
33. [FABP5 promotes cell growth, invasion and metastasis in cervical cancer].
Zhan YZ; Liu F; Zhang Y; Mo XY; Cheng WD; Wang W
Zhonghua Zhong Liu Za Zhi; 2019 Mar; 41(3):200-207. PubMed ID: 30917456
[No Abstract] [Full Text] [Related]
34. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
[TBL] [Abstract][Full Text] [Related]
35. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
37. Co-inhibitor expression on tumor infiltrating and splenic lymphocytes after dual checkpoint inhibition in a microsatellite stable model of colorectal cancer.
Slovak RJ; Park HJ; Kamp WM; Ludwig JM; Kang I; Kim HS
Sci Rep; 2021 Mar; 11(1):6956. PubMed ID: 33772035
[TBL] [Abstract][Full Text] [Related]
38. Garcinol exerts anti-cancer effect in human cervical cancer cells through upregulation of T-cadherin.
Zhao J; Yang T; Ji J; Li C; Li Z; Li L
Biomed Pharmacother; 2018 Nov; 107():957-966. PubMed ID: 30257408
[TBL] [Abstract][Full Text] [Related]
39. Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma.
Lacal PM; Atzori MG; Ruffini F; Scimeca M; Bonanno E; Cicconi R; Mattei M; Bernardini R; D'Atri S; Tentori L; Graziani G
Pharmacol Res; 2020 Sep; 159():104957. PubMed ID: 32485280
[TBL] [Abstract][Full Text] [Related]
40. Paclitaxel inhibits the progression of cervical cancer by inhibiting autophagy via lncRNARP11-381N20.2.
Zou SH; Du X; Lin H; Wang PC; Li M
Eur Rev Med Pharmacol Sci; 2018 May; 22(10):3010-3017. PubMed ID: 29863245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
